Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug 7;68(8):e0075024.
doi: 10.1128/aac.00750-24. Epub 2024 Jul 12.

Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)

Giacomo Ponta #  1   2 , Valentina Morena #  1 , Martina Strano  1   2 , Chiara Molteni  1 , Silvia Pontiggia  1 , Erica Michela Cavalli  3 , Anna Grancini  4 , Carola Mauri  5 , Antonella Castagna  2 , Andrea Galanti  6 , Stefania Piconi  1
Affiliations
Case Reports

Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)

Giacomo Ponta et al. Antimicrob Agents Chemother. .

Abstract

Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant Candida infections: a case of sacral osteomyelitis and a prosthetic valve endocarditis also involving a thoracic endovascular aneurysm repair.

Keywords: Candida; antifungal resistance; rezafungin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Weekly blood exams monitoring hemoglobin, transaminases, creatinine, and C-reactive protein since the start of rezafungin in Case 1.
Fig 2
Fig 2
Timeline of the main events of Case 1.
Fig 3
Fig 3
Weekly blood exams monitoring hemoglobin, transaminases, creatinine, and C-reactive protein since the start of rezafungin in Case 2.
Fig 4
Fig 4
Timeline of the main events of Case 2.
See this image and copyright information in PMC

Comment in

References

    1. Ordaya EE, Clement J, Vergidis P. 2023. The role of novel antifungals in the management of candidiasis: a clinical perspective. Mycopathologia 188:937–948. doi:10.1007/s11046-023-00759-5 - DOI - PMC - PubMed
    1. Tortorano AM, Prigitano A, Morroni G, Brescini L, Barchiesi F. 2021. Candidemia: evolution of drug resistance and novel therapeutic approaches. Infect Drug Resist 14:5543–5553. doi:10.2147/IDR.S274872 - DOI - PMC - PubMed
    1. Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, Viani RM, Sandison T, Pappas PG. 2021. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis 73:e3647–e3655. doi:10.1093/cid/ciaa1380 - DOI - PMC - PubMed
    1. Thompson GR, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, et al. . 2023. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet 401:49–59. doi:10.1016/S0140-6736(22)02324-8 - DOI - PubMed
    1. Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR, Pappas PG. 2024. Outcomes by Candida spp. in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrob Agents Chemother 68:e0158423. doi:10.1128/aac.01584-23 - DOI - PMC - PubMed

Publication types

LinkOut - more resources